SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-021008
Filing Date
2024-04-22
Accepted
2024-04-22 16:15:37
Documents
18
Period of Report
2023-06-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A lyel-20240614.htm   iXBRL DEF 14A 1374102
6 ny20023138x1_pvpchart01.jpg GRAPHIC 128693
7 ny20023138x1_lang-sig.jpg GRAPHIC 12834
8 ny20023138x1_pc01.jpg GRAPHIC 569595
9 ny20023138x1_pc02.jpg GRAPHIC 507561
  Complete submission text file 0001140361-24-021008.txt   5631876

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA lyel-20240614.xsd EX-101.SCH 5035
3 INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE lyel-20240614_def.xml EX-101.DEF 6320
4 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE lyel-20240614_lab.xml EX-101.LAB 11037
5 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE lyel-20240614_pre.xml EX-101.PRE 8983
21 EXTRACTED XBRL INSTANCE DOCUMENT lyel-20240614_htm.xml XML 382460
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

IRS No.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40502 | Film No.: 24861371
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)